A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia. [PDF]
Xia Y +10 more
europepmc +1 more source
Bing-Neel Syndrome in Waldenström Macroglobulinemia: Updates on Clinical Management and BTK Inhibitor Efficacy. [PDF]
Saburi M, Sekiguchi N.
europepmc +1 more source
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia. [PDF]
Castillo JJ +14 more
europepmc +1 more source
A Rare Combination: Cold Agglutinin Disease Followed by Waldenström Macroglobulinemia-A Case of Early Treatment Response. [PDF]
Kozub A +5 more
europepmc +1 more source
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. [PDF]
García-Sanz R +15 more
europepmc +1 more source
A real-world 10-year follow-up analysis of survival and safety of CD20-targeted therapy in patients with Waldenstrom macroglobulinemia. [PDF]
Zhang H +5 more
europepmc +1 more source
Successful Treatment of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Complicated by Severe Autoimmune Neutropenia With Rituximab and Bendamustine. [PDF]
Edahiro T +4 more
europepmc +1 more source
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis. [PDF]
Guijosa A +6 more
europepmc +1 more source
Waldenstrom’s Macroglobulinemia
Treon, S.P., Merlini, G., Dimopoulos, M.
openaire +1 more source

